# ASP Isotopes share price today (ASP Isotopes Inc., ASPI)

> ASP Isotopes Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ASPI · Materials · Chemicals · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/aspi

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $1.91 (−78.8% in a year)
- Revenue (Jun 2026): $5.1 M (+327.6% on a year ago)
- Profit (Jun 2026), incl. one-off: −$34.0 M (one-off item, see below)
- Operating margin: −667.5% (+331.6 points on a year ago)
- ROE: −67%, FY25
- ROIC: −17.9%, against a 13.6% cost of capital: −31.5 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the ASP Isotopes share price today? ASP Isotopes Inc.'s share price was $1.91 at the close on 4 November 2026. That is 60.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $9, and at that close it was at the low of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 17 weeks running. Over the last 1 year the share price moved −75% while the S&P 500 moved +23%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 10 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does ASP Isotopes pay? ASP Isotopes Inc. pays no dividend. In the last 11 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is ASP Isotopes on? ASP Isotopes is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is ASP Isotopes profitable? ASP Isotopes Inc. posted a net loss of $34.0 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $175 M. That loss is 663.5% of the quarter's revenue. The same quarter a year earlier lost $75.2 M. 11 of the last 11 reported quarters were loss-making. Read this profit with care: at −$34.0 M it is bigger than the quarter's whole revenue of $5.1 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −667.5% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does ASP Isotopes make, and is it growing? ASP Isotopes Inc. reported $5.1 M of revenue in the Jun 2026 quarter, +327.6% on the same quarter a year earlier. That is the 7th quarter in a row with growth on the year before. Over 2 years it has grown 642.1% a year on average. The last full year, FY25, came in at $23.8 M. The last four reported quarters add to $30.9 M. FY25 revenue was $23.8 M, +475.5% on the year before. Recent pace: the last four quarters grew +562.9% on average, against 642.1% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every $100 of sales does ASP Isotopes keep? ASP Isotopes Inc.'s operating margin was −667.5% in the Jun 2026 quarter, 331.6 percentage points higher than the same quarter a year ago. Across 3 years it has been between −3,704.8% and −239.8%. The latest quarter is within that range. Why the margin moved: operating margin changed +331.6 percentage points on the year while gross margin changed −18.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is ASP Isotopes' profit turning into cash? ASP Isotopes Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $37.8 M of cash, against −$175 M of profit. After $9.7 M of spending on assets, free cash was −$47.4 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does ASP Isotopes' cash go? ASP Isotopes Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $23.4 M on assets over the last 3 years. Averaged over those years that is 32.6% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $23.4 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is ASP Isotopes' P/E ratio, and how does it compare with its own history? ASP Isotopes Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values ASP Isotopes Inc. at 12.3× its FY25 revenue of $23.8 M. The P/E comes back here once profit turns positive. ## Is the ASP Isotopes business getting better or worse? ASP Isotopes Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 7 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does ASP Isotopes earn on its capital? ASP Isotopes Inc. earned a ROE of −67% in FY25. That is up from a low of −87% in FY23. Its return on capital used (ROIC) is 31.5 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −734.2% net margin and 0.05× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −734.2% net margin × 0.05× asset turnover × 1.89× leverage (assets divided by equity) ≈ −69.4% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −17.9% − 13.6% = −31.5 percentage points. The 13.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does ASP Isotopes have too much debt? ASP Isotopes Inc. has total debt of $270 M against shareholder equity of $275 M as of Jun 2026, so its debt is 0.98× its equity. Year by year, that ratio went from 0.15 in FY21 to 0.82 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the ASP Isotopes shareholding pattern? 21.8% of ASP Isotopes Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is ASP Isotopes from balance-sheet trouble? For ASP Isotopes Inc., the Z-score is 0.85. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 0.85 is inside the danger zone, so the balance sheet is a real risk. ## How does ASP Isotopes rank in its industry? 38.4 out of 100, rank 12 of 15 in Chemicals, with 61% of the evidence available. ASP Isotopes Inc. scores 38.4 out of 100 against the 15 companies it is compared with in Chemicals, ranking 12. Earnings are strong; relative strength in its sector is -57.9% and the one-year return is -78.8%. The four parts add up to the total exactly: 25.1 + 3 + 10 + 0.3 = 38.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is ASP Isotopes compared with? ASP Isotopes ranks 12 of 15 Chemicals companies on the 4-Factor Sector Score, with 38.4 out of 100. 1. [Methanex Corporation](https://www.sectoralpha.in/us/stocks/meoh) MEOH · breaking out · Most evidence points up · 81% evidence 75.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 19.2% · Profit -64.9% · Operating margin change 20.4 points · 83% evidence Capital efficiency 17.3/25 · ROCE 11.8% · Operating margin 37.1% · 76% evidence Valuation 14.0/20 · P/E 40.4× · PEG 0.17 · 65% evidence Relative strength 20.0/20 · Lead over its industry 36.9% · Lead over S&P 500 14.5% · 1 year 74.3% · 100% evidence · 8 of 12 weeks ahead Exact sum: 23.8 + 17.3 + 14 + 20 = 75.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [REX American Resources Corporation](https://www.sectoralpha.in/us/stocks/rex) REX · quiet · Most evidence points up · 85% evidence 71.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.4/35 · Revenue 1.2% · Profit 100% · Operating margin change 17.3 points · 95% evidence Capital efficiency 18.4/25 · ROCE 12.9% · Operating margin 22.4% · 76% evidence Valuation 14.7/20 · P/E 11.8× · PEG 0.25 · 65% evidence Relative strength 11.2/20 · Lead over its industry 9.3% · Lead over S&P 500 -8.7% · 1 year 23.6% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.4 + 18.4 + 14.7 + 11.2 = 71.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Westlake Chemical Partners LP](https://www.sectoralpha.in/us/stocks/wlkp) WLKP · turning · Most evidence points up · 81% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 12.1% · Profit 9.4% · Operating margin change -1.3 points · 83% evidence Capital efficiency 21.7/25 · ROCE 30.4% · Operating margin 29.4% · 76% evidence Valuation 10.1/20 · P/E 13.6× · PEG 1.57 · 65% evidence Relative strength 14.9/20 · Lead over its industry 12.8% · Lead over S&P 500 -5.5% · 1 year 15.6% · 100% evidence · 0 of 12 weeks ahead Exact sum: 20.4 + 21.7 + 10.1 + 14.9 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Dow Inc.](https://www.sectoralpha.in/us/stocks/dow) DOW · turning · Too little evidence to rank firmly · 58% evidence 56.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue n/a · Profit n/a · Operating margin change 4.9 points · 45% evidence Capital efficiency 10.5/25 · ROCE 0.9% · Operating margin 6.8% · 76% evidence Valuation 10.8/20 · P/E -12.3× · PEG n/a · 15% evidence Relative strength 17.5/20 · Lead over its industry 19.5% · Lead over S&P 500 -1.1% · 1 year 46.7% · 100% evidence · 3 of 12 weeks ahead Exact sum: 17.8 + 10.5 + 10.8 + 17.5 = 56.6 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [Celanese Corporation](https://www.sectoralpha.in/us/stocks/ce) CE · turning · Evidence leans up · 64% evidence 54.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.2/35 · Revenue -2.2% · Profit n/a · Operating margin change 1.2 points · 62% evidence Capital efficiency 12.9/25 · ROCE 5.2% · Operating margin 11% · 76% evidence Valuation 10.1/20 · P/E -4.3× · PEG n/a · 15% evidence Relative strength 15.4/20 · Lead over its industry 12.8% · Lead over S&P 500 -6.5% · 1 year 20.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 16.2 + 12.9 + 10.1 + 15.4 = 54.6 · What this means: Relative strength against the index is -6.5%, and revenue and profit growth are weak. 6. [LSB Industries, Inc.](https://www.sectoralpha.in/us/stocks/lxu) LXU · turning · Evidence leans up · 64% evidence 53.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/35 · Revenue 22.1% · Profit n/a · Operating margin change -10.2 points · 62% evidence Capital efficiency 10.7/25 · ROCE 6.1% · Operating margin -1.6% · 76% evidence Valuation 9.2/20 · P/E 23.3× · PEG n/a · 15% evidence Relative strength 12.9/20 · Lead over its industry 7% · Lead over S&P 500 -11.7% · 1 year 24.4% · 100% evidence · 1 of 12 weeks ahead Exact sum: 20.6 + 10.7 + 9.2 + 12.9 = 53.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Green Plains Inc.](https://www.sectoralpha.in/us/stocks/gpre) GPRE · quiet · Evidence leans up · 64% evidence 51.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue -23.7% · Profit n/a · Operating margin change 16.6 points · 62% evidence Capital efficiency 12.4/25 · ROCE 8.1% · Operating margin 15.2% · 76% evidence Valuation 9.9/20 · P/E 8.7× · PEG n/a · 15% evidence Relative strength 9.7/20 · Lead over its industry 8.1% · Lead over S&P 500 -10.2% · 1 year 35.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 19.6 + 12.4 + 9.9 + 9.7 = 51.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Valhi, Inc.](https://www.sectoralpha.in/us/stocks/vhi) VHI · quiet · Evidence leans down · 71% evidence 46.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.1/35 · Revenue 3.4% · Profit -127.5% · Operating margin change 7 points · 83% evidence Capital efficiency 9.2/25 · ROCE -0.4% · Operating margin 6.7% · 76% evidence Valuation 10.6/20 · P/E -8.1× · PEG n/a · 15% evidence Relative strength 15.8/20 · Lead over its industry 18.3% · Lead over S&P 500 -0.4% · 1 year 9.3% · 100% evidence · 5 of 12 weeks ahead Exact sum: 11.1 + 9.2 + 10.6 + 15.8 = 46.7 · What this means: Relative strength against the index is -0.4%, and revenue and profit growth are weak. 9. Ascent Industries Co. ACNT · basing · Evidence leans down · 64% evidence 43.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.0/35 · Revenue 10.5% · Profit n/a · Operating margin change 8.2 points · 62% evidence Capital efficiency 4.5/25 · ROCE -6.6% · Operating margin -0.3% · 76% evidence Valuation 11.3/20 · P/E -30.6× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry 3.4% · Lead over S&P 500 -12.7% · 1 year 8.3% · 100% evidence · 2 of 12 weeks ahead Exact sum: 19 + 4.5 + 11.3 + 8.3 = 43.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Huntsman Corporation](https://www.sectoralpha.in/us/stocks/hun) HUN · quiet · Evidence leans down · 64% evidence 39.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.8/35 · Revenue 0.7% · Profit n/a · Operating margin change 1.1 points · 62% evidence Capital efficiency 6.3/25 · ROCE -1.2% · Operating margin 1.7% · 76% evidence Valuation 11.5/20 · P/E -45.8× · PEG n/a · 15% evidence Relative strength 8.9/20 · Lead over its industry -0.8% · Lead over S&P 500 -18.1% · 1 year 21.6% · 100% evidence · 0 of 12 weeks ahead Exact sum: 12.8 + 6.3 + 11.5 + 8.9 = 39.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Olin Corporation](https://www.sectoralpha.in/us/stocks/oln) OLN · basing · Evidence leans down · 64% evidence 38.6 out of 100 Growth Capital Valuation Relative
12. ASP Isotopes Inc. this page ASPI · quiet · Evidence leans down · 61% evidence 38.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 100% · Profit n/a · Operating margin change 331.6 points · 62% evidence Capital efficiency 3.0/25 · ROCE -19.2% · Operating margin -667.5% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 0.3/20 · Lead over its industry -57.9% · Lead over S&P 500 -64.9% · 1 year -78.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.1 + 3 + 10 + 0.3 = 38.4 · What this means: Earnings are strong; relative strength in its sector is -57.9% and the one-year return is -78.8%. 13. [Rayonier Advanced Materials Inc.](https://www.sectoralpha.in/us/stocks/ryam) RYAM · quiet · Most evidence points down · 64% evidence 33.7 out of 100 Growth Capital Valuation Relative
14. [AdvanSix Inc.](https://www.sectoralpha.in/us/stocks/asix) ASIX · basing · Most evidence points down · 71% evidence 32.5 out of 100 Growth Capital Valuation Relative
15. [Tronox Holdings plc](https://www.sectoralpha.in/us/stocks/trox) TROX · quiet · Most evidence points down · 64% evidence 24.9 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals](https://www.sectoralpha.in/us/sectors/chemicals), all 15 compared on one page. ## Which companies are close to ASP Isotopes in size? ASP Isotopes is the 15th largest of 15 Chemicals companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Westlake Chemical Partners LP, Tronox Holdings plc, Rayonier Advanced Materials Inc., Braskem S.A., Valhi, Inc. and AdvanSix Inc. It is the smallest. ### Chemicals companies close in size

1. [Westlake Chemical Partners LP](https://www.sectoralpha.in/us/stocks/wlkp) $762 million
2. [Tronox Holdings plc](https://www.sectoralpha.in/us/stocks/trox) $567 million
3. [Rayonier Advanced Materials Inc.](https://www.sectoralpha.in/us/stocks/ryam) $484 million
4. [Braskem S.A.](https://www.sectoralpha.in/us/stocks/bak) $456 million
5. [Valhi, Inc.](https://www.sectoralpha.in/us/stocks/vhi) $431 million
6. [AdvanSix Inc.](https://www.sectoralpha.in/us/stocks/asix) $419 million
7. ASP Isotopes Inc. $293 million

[All 15 Chemicals companies, largest first](https://www.sectoralpha.in/us/sectors/chemicals#all-companies)

### Companies close in size in other industries

1. [Treace Medical Concepts, Inc.](https://www.sectoralpha.in/us/stocks/tmci) $278 million · Medical Devices
2. [Community Health Systems, Inc.](https://www.sectoralpha.in/us/stocks/cyh) $278 million · Medical Care Facilities
3. ASP Isotopes Inc. $277 million
4. [Perma-Fix Environmental Services, Inc.](https://www.sectoralpha.in/us/stocks/pesi) $277 million · Waste Management
5. [A2Z Cust2Mate Solutions Corp.](https://www.sectoralpha.in/us/stocks/az) $276 million · Software - Application

## What else do people ask about ASP Isotopes? ### What were ASP Isotopes's latest quarterly results? ASP Isotopes Inc. reported revenue of $5.1 M and a net loss of $34.0 M for the Jun 2026 quarter. Earnings per share were −$0.27. The operating margin was −667.5%, 331.6 percentage points higher than a year earlier (as of 4 November 2026). ### What is ASP Isotopes's market cap? ASP Isotopes Inc.'s market capitalisation is $293 M at a stock price of $1.91. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is ASP Isotopes performing? ASP Isotopes Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 17 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will ASP Isotopes's stock price go up? This page does not forecast ASP Isotopes Inc.'s stock price. What it shows instead: the stock price is $1.91. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is ASP Isotopes in its business cycle? ASP Isotopes Inc.'s FY25 operating margin was −239.8%, against a 3-year range of −3,704.8% to −239.8%: the middle of its own range, neither a peak nor a low. The latest quarter was −667.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the ASP Isotopes story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is ASP Isotopes a stock worth studying right now? What the numbers show: ASP Isotopes Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.